// App-Quantinova.ai

2040 : Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Long-Term Efficacy and Safety Results from a Phase 2 Study

Researchers

Presenter

  • Michael Wang

Principal Investigators

  • Pier Luigi Zinzani

  • Andre H. Goy

  • Rene-Olivier Casasnovas

  • Stephen D. Smith

  • Gandhi Laurent Damaj

  • Jeanette K. Doorduijn

  • Thierry Lamy

  • Franck Morschhauser

  • Carlos Panizo

  • Bijal Shah

  • Andrew Davies

  • Richard Eek

  • Jehan Dupuis

  • Eric Jacobsen

  • Arnon P. Kater

  • Steven Le Gouill

  • Lucie Oberic

  • Tadeusz Robak

  • Preetesh Jain

  • Graham Brock

  • Priti Patel

  • Lin Tao

  • Monika Dlugosz-Danecka

Medical Centers

  • MD Anderson Cancer Center, University of Texas, Houston, TX

  • Plymouth University Medical School, Plymouth, United Kingdom

  • Institute of Hematology, University of Bologna, Bologna, Italy

  • John Theurer Cancer Centre, Hackensack University Medical Center, Hackensack, NJ

  • CHU Dijon - Hôpital d'Enfants, Dijon, France

  • Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA

  • Institut d'Hematologie de Basse Normandie, Caen, France

  • Erasmus MC, HOVON Lunenburg Lymphoma Phase I/II Consortium, Rotterdam, Netherlands

  • CHU Rennes, Rennes, France

  • Clinica Universidad de Navarra, Pamplona, Spain

  • Moffitt Cancer Center, Tampa, FL

  • Cancer Research UK/NIHR Experimental Cancer Medicines Centre, University of Southampton,Southampton,United Kingdom

  • Border Medical Oncology, Albury-Wodonga, Australia

  • Unite Hemopathies Lymphoides, AP-HP Hopital Henri Mondor, Creteil, France

  • Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA

  • Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, HOVON Lunenburg Lymphoma Phase I/II Consortium, Amsterdam, Netherlands

  • CHU de Nantes - Hotel Dieu, Nantes, France

  • Institut Universitaire du cancer, Oncopole IUCT, Toulouse, France

  • Copernicus Memorial Hospital, Medical University of Lodz, Lodz, Poland

  • Acerta Pharma, South San Francisco, CA

  • The Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw,Warsaw,Poland

Locations

  • United States

  • United Kingdom

  • Italy

  • France

  • Netherlands

  • Spain

  • Australia

  • Poland

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Mantle cell lymphoma

Biomarkers

  • Bruton tyrosine kinase

Drug/Treatment

  • ACP-196

  • Warfarin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT02213926

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved